ISPOR ANNOUNCES CANDIDATES FOR 2016–2017 BOARD OF DIRECTORS

Published Feb 29, 2016
Princeton, NJ—February 29, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced its candidates today for open positions on the 2016–2017 Board of Directors. The Board of Directors drives ISPOR's strategic direction and is responsible for the management of the Society, including its committees, publications, budget and governance. The Board is the policy making body of the Society.  The positions and candidates for the 2016–2017 ISPOR Board of Directors include: President-Elect - Newell McElwee, PharmD, MSPH Associate Vice President, Merck (North Wales, PA, USA) - Shelby D. Reed, PhD, RPh Professor, Duke University (Durham, NC, USA) Director - Mirjana Huic, MD, MSc, PhD Assistant Director, Croatia Agency for Quality and Accreditation in Health Care and Social Work (Zagreb, Croatia) - Joanna Lis, PhD, MSc, MBA Director of Market Access, Sanofi-Aventis (Warsaw, Poland) Director - Brian Solow, MD, FAAFP Chief Medical Officer, Optum Life Sciences (Irvine, CA, USA) - John Watkins, PharmD, MPH Formulary Manager, Premera Blue Cross (Mountlake Terrace, WA, USA) Director - Nathorn Chaiyakunapruk, PharmD, PhD Professor, School of Pharmacy, Monash University (Selangor, Malaysia) - Gordon Liu, PhD Professor of Economics, Peking University, National School of Development (Bejing, China) Director - Rosanna Tarricone, PhD, MSc Associate Professor, Bocconi University (Milan, Italy) - Mondher Toumi, MD, MSc, PhD Professor, University Aix-Marseille (Paris, France) ISPOR members will be invited to vote beginning March 1 with elections closing on May 1, 2016. Information on each of the candidates–including biographies and vision statements–can be found on the ISPOR Board of Directors Elections webpage. Only ISPOR global members are eligible to vote in the elections. Information about the Society and the benefits of membership can be found here.

###

Related Stories

ISPOR Announces New Strategic Plan 2030

Jul 29, 2024

ISPOR announced its new Strategic Plan 2030 that presents a bold new vision for the Society and the field of health economics and outcomes research (HEOR).

Measuring What Matters: Broadening the Scope of Health Economics Evaluation to Incorporate Well-Being

Jul 9, 2024

ISPOR announced the publication of a special themed section of research papers in Value in Health that offer insights into facets of economic evaluation aimed to incorporate well-being into decision making.

Confronting the Backlash Against QALYs: Key Insights From Leading Health Economists

Jun 18, 2024

ISPOR announced the publication of a collection of papers that examine the long-standing debate surrounding the use of quality-adjusted life years (QALYs) and alternative measures in healthcare decision making.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×